NCT06269133Active, not recruiting
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants
Evaluating the Safety and Effectiveness of Cemiplimab in Combination With Platinum-Doublet Chemotherapy by Demographic Characteristics in First-Line Treatment of Advanced Non-Small Cell Lung Cancer: A Multi-Database Real World Evidence Study in US Patients
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
This multi-year cohort study will assess the real-world safety and effectiveness of first Line (1L) treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC participant subgroups defined by age, sex, race, and ethnicity. Participants will be retrospectively identified from at least two US Electronic Health Record (EHR)-based databases.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 13 Feb 2024
- Start date
- 21 Feb 2024
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Regeneron Pharmaceuticals
- Diseases
- Lung cancer
- NCT number
- NCT06269133
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 21 Feb 2024 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants actively enrolled in a clinical trial in which they receive treatment with cemiplimab in combination with platinum-doublet chemotherapy
- Note: Other protocol-defined Inclusion/ Exclusion Criteria apply
Lab values
- Participants who have EGFR, ALK or ROS1 variants
- Treatment with EGFR, ALK or ROS1 inhibitors at any time prior to the index date
Who the study is looking for
- 1\. Advanced non-small cell lung cancer (aNSCLC) (defined as stage IIIB/C or stage IV) treated with cemiplimab in combination with platinum-doublet chemotherapy in the 1L setting from Nov 2022 to Jun 2026 as described in the protocol
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Regeneron Research Facility Coordinator of this site? Confirm its status | Tarrytown | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.